Lundbeck has initiated phase I trial of acquired candidate
![In October, Lundbeck bought a phase I ready candidate from Aprilbio. Now, it's been sent to clinic | Photo: Mik Eskestad/ERH](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article14020497.ece/ALTERNATES/schema-16_9/doc7l0lwxvkmgg62tfvj4t.jpg)
For the first time, a person has been dosed with Lu AG22515, a candidate that Lundbeck acquired for USD 16m upfront payment from South Korean biotech company Aprilbio in October last year, in a deal which also included potential milestone payments of USD 432m.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.